Jade Biosciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is JBIO moving today?
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for JBIO.
JBIO insider activity
Jade Biosciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for JBIO.
JBIO contract awards, year to date.
Public federal awards linked to this ticker.
JBIO lobbying filings, year to date.
Registered lobbying filings matched to Jade Biosciences, Inc. Common Stock.